

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Condensed Balance Sheets(Reviewed, Not Audited)**  
**Nine Months Ended September 30, 2016 and 2015**

Unit : NT\$ Thousands

<u>Assets</u>		<u>September 30, 2016</u>		<u>December 31, 2015</u>		<u>September 30, 2015</u>	
		<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>
<b>Current Assets</b>							
1100	Cash and Cash Equivalents	\$ 684,853	7	\$ 701,797	7	\$ 722,835	7
1147	Current Investments in Debt Instrument Without						
	Active Market	16,000	-	20,000	-	-	-
1150	Notes Receivable	338,432	3	338,188	3	386,016	4
1160	Notes Receivable – Related Parties	190,035	2	167,119	2	149,937	1
1170	Accounts Receivable	1,077,533	11	1,064,551	11	1,012,894	10
1180	Accounts Receivable – Related Parties	53,538	1	67,118	1	79,376	1
1200	Other Receivables	53,416	1	28,724	-	100,629	1
1210	Other Receivables –Related Parties	181,065	2	164,305	2	164,606	2
1220	Current Income Tax Assets	18,512	-	3,714	-	-	-
130X	Inventories	1,499,779	15	1,485,334	15	1,511,120	15
1410	Prepayments	73,065	1	53,995	1	64,870	1
1476	Other Financial Assets- Current	16,864	-	31,500	-	29,924	-
11XX	<b>Total Current Assets</b>	<u>4,203,092</u>	<u>43</u>	<u>4,126,345</u>	<u>42</u>	<u>4,222,207</u>	<u>42</u>
<b>Non-Current assets</b>							
1523	Available-for-sale Financial Assets- Noncurrent	273,633	3	277,470	3	253,715	3
1543	Financial Assets at Cost - Noncurrent	30,710	-	30,710	-	30,710	-
1550	Long-term Investments at Equity	797,117	8	793,084	8	758,315	8
1600	Property, Plant and Equipment	4,192,400	43	4,265,256	43	4,283,360	43
1780	Intangible Assets	7,936	-	9,408	-	9,049	-
1840	Deferred Tax Assets	132,917	1	169,460	2	172,894	2
1900	Other Non-current Assets	167,130	2	241,172	2	233,239	2
15XX	<b>Total Non-Current Assets</b>	<u>5,601,843</u>	<u>57</u>	<u>5,786,560</u>	<u>58</u>	<u>5,741,282</u>	<u>58</u>
1XXX	<b>Total Assets</b>	<u>\$ 9,804,935</u>	<u>100</u>	<u>\$ 9,912,905</u>	<u>100</u>	<u>\$ 9,963,489</u>	<u>100</u>

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Condensed Balance Sheets(Reviewed, Not Audited)**  
**Nine Months Ended September 30, 2016 and 2015**

Unit : NT\$ Thousands

<b>Liabilities and Shareholders' Equity</b>		September 30, 2016		December 31, 2015		September 30, 2015	
		Amount	%	Amount	%	Amount	%
<b>Current Liabilities</b>							
2100	Short-term Borrowings	\$ 1,062,033	11	\$ 1,045,407	11	\$ 1,159,527	12
2110	Short-Term Notes and Bills Payable	84,994	1	73,994	1	118,000	1
2150	Notes Payable	84,306	1	156,857	2	139,271	1
2170	Accounts Payable	618,228	6	573,830	6	559,347	6
2200	Other Payables	268,987	3	298,406	3	266,427	3
2230	Current Income Tax Liabilities	22,448	-	17,759	-	15,854	-
2250	Short-term Provisions	63,027	1	53,158	-	49,000	1
2300	Other Current Liabilities	27,937	-	52,871	-	35,083	-
21XX	<b>Total Non-Current Liabilities</b>	<u>2,231,960</u>	<u>23</u>	<u>2,272,282</u>	<u>23</u>	<u>2,342,509</u>	<u>24</u>
<b>Non-Current Liabilities</b>							
2540	Long-term Borrowings	1,718,000	18	1,599,000	16	1,595,000	16
2570	Deferred Income Tax Liabilities	117,896	1	129,095	2	143,786	1
2600	Other Non-Current Liabilities	221,906	2	423,071	4	401,663	4
25XX	<b>Total Non-Current Liabilities</b>	<u>2,057,802</u>	<u>21</u>	<u>2,151,166</u>	<u>22</u>	<u>2,140,449</u>	<u>21</u>
2XXX	<b>Total Liabilities</b>	<u>4,289,762</u>	<u>44</u>	<u>4,423,448</u>	<u>45</u>	<u>4,482,958</u>	<u>45</u>
<b>Equity Attributable to Owners of Parent</b>							
<b>Share Capital</b>							
3110	Ordinary Share	2,980,811	30	2,980,811	30	2,980,811	30
<b>Capital Surplus</b>							
3200	Capital Surplus	642,640	7	642,640	6	642,640	7
<b>Retained Earnings</b>							
3310	Legal Reserve	397,599	4	362,229	4	362,229	4
3320	Special Reserve	188,958	2	188,958	2	188,958	2
3350	Unappropriated Retained Earnings	1,228,138	12	1,161,478	12	1,152,525	11
<b>Other Equity Interest</b>							
3400	Other Interest	55,922	1	132,931	1	133,369	1
3500	Treasury Stock	( 28,054)	-	( 28,054)	-	( 28,054)	-
31XX	<b>Total Equity Attributable to Shareholders of the Parent</b>	<u>5,466,014</u>	<u>56</u>	<u>5,440,993</u>	<u>55</u>	<u>5,432,478</u>	<u>55</u>
36XX	<b>Noncontrolling Interests</b>	<u>49,159</u>	<u>-</u>	<u>48,464</u>	<u>-</u>	<u>48,053</u>	<u>-</u>
3XXX	<b>Total Shareholders' Equity</b>	<u>5,515,173</u>	<u>56</u>	<u>5,489,457</u>	<u>55</u>	<u>5,480,531</u>	<u>55</u>
Significant Contingent Liability&Unrealized Contractual Arrangement							
3X2X	<b>Total Liabilities &amp; Shareholders' Equity</b>	<u>\$ 9,804,935</u>	<u>100</u>	<u>\$ 9,912,905</u>	<u>100</u>	<u>\$ 9,963,489</u>	<u>100</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Comprehensive Income(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2016 and 2015**

Unit : NT\$ Thousands  
(EPS: NT Dollars)

Item	For the Three Months Ended September 30				For the Nine Months Ended September 30			
	2016		2015		2016		2015	
	A m o u n t	%	A m o u n t	%	A m o u n t	%	A m o u n t	%
4000 Operating Revenue	\$ 1,385,208	100	\$ 1,370,991	100	\$ 4,353,766	100	\$ 4,196,604	100
5000 Operating Costs	( 986,651)	( 71)	( 996,179)	( 73)	( 3,074,430)	( 71)	( 2,972,512)	( 71)
5950 <b>Gross Profit from Operations</b>	<u>398,557</u>	<u>29</u>	<u>374,812</u>	<u>27</u>	<u>1,279,336</u>	<u>29</u>	<u>1,224,092</u>	<u>29</u>
<b>Operating Expenses</b>								
6100 Selling Expenses	( 216,298)	( 16)	( 209,918)	( 15)	( 648,331)	( 15)	( 635,694)	( 15)
6200 Administrative Expenses	( 45,173)	( 3)	( 47,194)	( 4)	( 134,791)	( 3)	( 137,104)	( 3)
6300 Research and Development Expenses	( 80,435)	( 6)	( 84,867)	( 6)	( 238,337)	( 5)	( 246,406)	( 6)
6000 <b>Total Operating Expenses</b>	<u>( 341,906)</u>	<u>( 25)</u>	<u>( 341,979)</u>	<u>( 25)</u>	<u>( 1,021,459)</u>	<u>( 23)</u>	<u>( 1,019,204)</u>	<u>( 24)</u>
6900 <b>Net Operating Income</b>	<u>56,651</u>	<u>4</u>	<u>32,833</u>	<u>2</u>	<u>257,877</u>	<u>6</u>	<u>204,888</u>	<u>5</u>
<b>Non- Operating Income and Expenses</b>								
7010 Other Revenue	9,041	1	62,162	5	33,357	1	107,799	3
7020 Other Gains and Losses	9,123	1	28,617	2	17,857	-	23,207	1
7050 Finance Cost	( 10,063)	( 1)	( 9,239)	( 1)	( 27,904)	( 1)	( 28,745)	( 1)
7060 Share of Profit or Loss of Associates & Joint Ventures Accounted for Using Equity Method)	<u>16,956</u>	<u>1</u>	<u>26,099</u>	<u>2</u>	<u>63,153</u>	<u>2</u>	<u>96,055</u>	<u>2</u>
7000 <b>Total Non-Operating Income and Expenses</b>	<u>25,057</u>	<u>2</u>	<u>107,639</u>	<u>8</u>	<u>86,463</u>	<u>2</u>	<u>198,316</u>	<u>5</u>
7900 <b>Income Before Income Tax</b>	<u>81,708</u>	<u>6</u>	<u>140,472</u>	<u>10</u>	<u>344,340</u>	<u>8</u>	<u>403,204</u>	<u>10</u>
7950 Income Tax Expense	( 14,646)	( 1)	( 19,498)	( 1)	( 58,438)	( 1)	( 74,877)	( 2)
8200 <b>Net Income</b>	<u>\$ 67,062</u>	<u>5</u>	<u>\$ 120,974</u>	<u>9</u>	<u>\$ 285,902</u>	<u>7</u>	<u>\$ 328,327</u>	<u>8</u>
<b>Other Comprehensive Income that will be Reclassified to Profit or Loss</b>								
8361 Exchange Differences on Translation of Foreign Financial Statements	(\$ 39,943)	( 3)	\$ 48,999	4	(\$ 85,815)	( 2)	\$ 18,564	-
8362 Unrealised Gains (Losses) on Valuation of Available-for-sale Financial Assets	( 2,551)	-	( 96,465)	( 7)	( 3,837)	-	( 182,067)	( 4)
8370 Share of Other Comprehensive Income (Loss) of Subsidiaries and Associates Equity Method - Will be Reclassified to Profit	( 324)	-	( 2,243)	-	( 1,945)	-	( 3,566)	-
8399 Income Tax Relating to Components of Other Comprehensive Income	<u>6,790</u>	<u>-</u>	<u>( 8,330)</u>	<u>( 1)</u>	<u>14,588</u>	<u>-</u>	<u>( 3,156)</u>	<u>-</u>
8360 <b>Total Components of Other Comprehensive Income That Will be Reclassified to Profit or Loss</b>	<u>( 36,028)</u>	<u>( 3)</u>	<u>( 58,039)</u>	<u>( 4)</u>	<u>( 77,009)</u>	<u>( 2)</u>	<u>( 170,225)</u>	<u>( 4)</u>
8300 <b>Net Other Comprehensive Income and Loss After Tax</b>	<u>(\$ 36,028)</u>	<u>( 3)</u>	<u>(\$ 58,039)</u>	<u>( 4)</u>	<u>(\$ 77,009)</u>	<u>( 2)</u>	<u>(\$ 170,225)</u>	<u>( 4)</u>
8500 <b>Total Comprehensive Income</b>	<u>\$ 31,034</u>	<u>2</u>	<u>\$ 62,935</u>	<u>5</u>	<u>\$ 208,893</u>	<u>5</u>	<u>\$ 158,102</u>	<u>4</u>
<b>Net Income (Losses) Attributable to:</b>								
8610 Shareholders of the Parent	<u>\$ 67,380</u>	<u>5</u>	<u>\$ 118,829</u>	<u>9</u>	<u>\$ 280,879</u>	<u>7</u>	<u>\$ 323,659</u>	<u>8</u>
8620 Non-controlling Interests	<u>(\$ 318)</u>	<u>-</u>	<u>\$ 2,145</u>	<u>-</u>	<u>\$ 5,023</u>	<u>-</u>	<u>\$ 4,668</u>	<u>-</u>
<b>Comprehensive Income Attributable to:</b>								
8710 Shareholders of the Parent	<u>\$ 31,352</u>	<u>2</u>	<u>\$ 60,790</u>	<u>4</u>	<u>\$ 203,870</u>	<u>5</u>	<u>\$ 153,434</u>	<u>4</u>
8720 Non-controlling Interests	<u>(\$ 318)</u>	<u>-</u>	<u>\$ 2,145</u>	<u>-</u>	<u>\$ 5,023</u>	<u>-</u>	<u>\$ 4,668</u>	<u>-</u>
<b>Earnings per Share</b>								
9750 <b>Diluted Earnings Per Share</b>		<u>0.23</u>		<u>0.40</u>		<u>0.94</u>		<u>1.09</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statement of Changes in Equity (Reviewed, Not Audited)**  
**Nine months Ended September 30, 2016 and 2015**

Unit : NT\$ Thousands

	T o t a l      E q u i t y      A t t r i b u t a b l e      t o      O w n e r s      o f      P a r e n t											
	Ordinary Share	Additional Paid-In Capital	Treasury Stock Transac- tions	Legal Reserve	Special Reserve	Unappropri- ated Retained Earnings	Exchange Differences on Translation	Equity Unrealized Gains(Losse s)on Availablefor -sale Financial Assets	Treasury Stock	Total	Non-contr olling Interests	Total Equity
<b>January 1st to September 30, 2015</b>												
Equity at Beginning Of Period	\$ 2,980,811	\$ 578,416	\$ 63,868	\$ 327,457	\$ 188,958	\$ 1,042,487	\$ 63,345	\$ 240,249	(\$ 28,054 )	\$ 5,457,537	\$ 26,015	\$ 5,483,552
Appropriation and Distribution of Retained Earnings of 2014												
Legal Reserve	-	-	-	34,772	-	( 34,772 )	-	-	-	-	-	-
Cash Dividends	-	-	-	-	-	( 178,849 )	-	-	-	( 178,849 )	-	( 178,849 )
Subsidiaries Acquired Cash Dividend Payment of Parent Company	-	-	356	-	-	-	-	-	-	356	141	497
Consolidated Income (Loss)	-	-	-	-	-	323,659	-	-	-	323,659	4,668	328,327
Other Comprehensive Income (Loss)	-	-	-	-	-	-	15,550	( 185,775 )	-	( 170,225 )	-	( 170,225 )
Changes in Non-controlling Interests	-	-	-	-	-	-	-	-	-	-	17,229	17,229
<b>Balance, September 30, 2015</b>	<u>\$ 2,980,811</u>	<u>\$ 578,416</u>	<u>\$ 64,224</u>	<u>\$ 362,229</u>	<u>\$ 188,958</u>	<u>\$ 1,152,525</u>	<u>\$ 78,895</u>	<u>\$ 54,474</u>	<u>(\$ 28,054 )</u>	<u>\$ 5,432,478</u>	<u>\$ 48,053</u>	<u>\$ 5,480,531</u>
<b>January 1st to September 30, 2016</b>												
Equity at Beginning Of Period	\$ 2,980,811	\$ 578,416	\$ 64,224	\$ 362,229	\$ 188,958	\$ 1,161,478	\$ 51,707	\$ 81,224	(\$ 28,054 )	\$ 5,440,993	\$ 48,464	\$ 5,489,457
Appropriation and Distribution of Retained Earnings of 2015												
Legal Reserve	-	-	-	35,370	-	( 35,370 )	-	-	-	-	-	-
Cash Dividends	-	-	-	-	-	( 178,849 )	-	-	-	( 178,849 )	-	( 178,849 )
Legal Reserve	-	-	-	-	-	-	-	-	-	-	-	-
Cash Dividends	-	-	-	-	-	( 178,849 )	-	-	-	( 178,849 )	-	( 178,849 )
Consolidated Income (Loss)	-	-	-	-	-	280,879	-	-	-	280,879	5,023	285,902
Other Comprehensive Income (Loss)	-	-	-	-	-	-	( 71,372 )	( 5,637 )	-	( 77,009 )	-	( 77,009 )
Changes in Non-controlling Interests	-	-	-	-	-	-	-	-	-	-	( 4,328 )	( 4,328 )
<b>Balance, September 30, 2016</b>	<u>\$ 2,980,811</u>	<u>\$ 578,416</u>	<u>\$ 64,224</u>	<u>\$ 397,599</u>	<u>\$ 188,958</u>	<u>\$ 1,228,138</u>	<u>(\$ 19,665 )</u>	<u>\$ 75,587</u>	<u>(\$ 28,054 )</u>	<u>\$ 5,466,014</u>	<u>\$ 49,159</u>	<u>\$ 5,515,173</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2016 and 2015**

Unit : NT\$ Thousands

**For the Nine Months Ended September 30**

September, 2016      September, 2015

**Cash Flows From (Used in) Operating Activities**

Consolidated Profit (Loss) Before Tax	\$	344,340	\$	403,204
Depreciation expense		186,483		179,649
Amortized Expense		1,207		1,331
Bad Debts Recognized Revenue		3,547	(	563)
Decrease in Allowance for Sales Returns and Allowances	(	2,532)		1,799
Interest Expense		27,904		28,745
Interest Revenue	(	8,425)	(	9,098)
Dividend Revenue	(	9,091)	(	11,013)
Share of gain (loss) of Associates and Joint Ventures Accounted for Using Equity Method	(	63,153)	(	96,055)
Gain on Disposal of Property, Plant and Equipment	(	682)	(	36,692)
Notes Receivable (Include Related Parties)	(	28,178)	(	30,128)
Accounts Receivable (Include Related Parties)	(	6,499)	(	30,737)
Other Receivable (Include Related Parties)	(	15,908)		5,882
Inventories	(	42,271)		43,658
Prepayments	(	19,154)	(	3,099)
Notes Payable	(	64,529)		48,142
Accounts Payable		46,801		16,212
Other Payable	(	19,458)	(	61,208)
Short-term Provision		9,869	(	49,980)
Other Current Liabilities	(	24,030)	(	1,043)
Other Non-Current Liabilities	(	189,875)	(	9,962)
<b>Cash Inflow (Outflow) Generated from Operations</b>		<u>126,366</u>		<u>389,044</u>
Interest Received		8,708		9,121
Cash Dividends Received		66,268		46,637
Interest Paid	(	28,213)	(	29,450)
Income Taxes Refund (Paid)	(	27,586)	(	98,449)
<b>Net Cash Flows from (used in) Operating Activities</b>		<u>145,543</u>		<u>316,903</u>

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2016 and 2015**

Unit : NT\$ Thousands

**For the Nine Months Ended September 30**

September, 2016      September, 2015

**Cash Flows From (Used in) Investing Activities**

Disposal of Current Investments in Debt Instrument Without Active			
Market	\$	4,000	\$ -
Decrease(Increase) in Financing Receivable	(	22,994)	( 56,666)
Decrease(Increase) in Pledged Deposit		14,636	( 12,202)
Acquired Financial Assets at Cost - Noncurrent		-	( 15,000)
Purchase of Property, Plant and Equipment	(	89,294)	( 182,170)
Disposal of Property, Plant and Equipment		1,753	239,459
Decrease(Increase) in Refundable Deposits		2,622	( 1,353)
Decrease(Increase) in Prepaid Investment		-	30,000
Decrease(Increase) in Other Non-current Assets		4,573	-
Acquisition of Subsidiaries (Deduct Cash acquired)	(	7,783)	-
<b>Net Cash Flows From (Used in) Investing Activities</b>	(	<u>92,487</u> )	<u>2,068</u>

**Cash flows from (used in) Financing Activities**

Decrease(Increase) In Short-term Borrowings		16,626	( 158,682)
Decrease(Increase) in Short-term Notes and Bills Payable		11,000	( 54,978)
Proceeds from Long-term Borrowings		261,000	550,000
Repayment of Long-term Borrowings	(	142,000)	( 580,000)
Decrease(Increase) in Guarantee Deposits Received	(	9,968)	1,386
Assigned Cash Dividends	(	178,849)	( 178,849)
Acquired Cash Dividends By Minority Interest	(	4,328)	( 2,771)
Non-controlling Interests change		-	<u>20,000</u>
Net cash FlowsFrom (Used in) Financing Activities	(	<u>46,519</u> )	<u>403,894</u> )
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(	<u>23,481</u> )	<u>11,851</u>
Net Increase (Decrease) In Cash and Cash Equivalents	(	16,944)	( 73,072)
Cash and Cash Equivalents at Beginning of Period		<u>701,797</u>	<u>795,907</u>
Cash and Cash Equivalents at End of Period	\$	<u><u>684,853</u></u>	\$ <u><u>722,835</u></u>